4 236

Cited 7 times in

Pharmacokinetic Interaction Between Rosuvastatin and Metformin in Healthy Korean Male Volunteers: A Randomized, Open-label, 3-period, Crossover, Multiple-dose Study

 Donghwan Lee  ;  Hyerang Roh  ;  Hankil Son  ;  Seong Bok Jang  ;  Seoungoh Lee  ;  Su Youn Nam  ;  Kyungsoo Park 
 CLINICAL THERAPEUTICS, Vol.36(8) : 1171-1181, 2014 
Journal Title
Issue Date
Administration, Oral ; Adult ; Area Under Curve ; Asian Continental Ancestry Group ; Cross-Over Studies ; Drug Interactions ; Drug Therapy, Combination/adverse effects ; Healthy Volunteers ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics* ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/pharmacokinetics* ; Male ; Metformin/administration & dosage ; Metformin/adverse effects ; Metformin/pharmacokinetics* ; Middle Aged ; Republic of Korea ; Rosuvastatin Calcium/administration & dosage ; Rosuvastatin Calcium/adverse effects ; Rosuvastatin Calcium/pharmacokinetics* ; Young Adult
Drug–drug interaction ; metformin ; pharmacokinetics ; rosuvastatin
PURPOSE: Rosuvastatin is indicated for hypercholesterolemia or dyslipidemia and metformin mainly for type 2 diabetes. These 2 drugs are frequently prescribed in combination due to the high comorbidity of the 2 diseases. However the nature of pharmacokinetic interaction between the 2 drugs has not been previously investigated. The purpose of our study was to investigate the pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers. METHODS: This was a randomized, open-label, 6-sequence, 3-period, crossover, multiple-dose study. Eligible subjects, aged 20 to 50 years and within 20% of the ideal body weight, received 1 of the following 3 treatments for each period once daily for 5 consecutive days with a 10-day washout period between the treatments: monoadministration of rosuvastatin 10 mg tablet, monoadministration of metformin 750 mg tablet, and coadministration of rosuvastatin 10 mg tablet with metformin 750 mg tablet. Blood samples were collected up to 72 hours after the last dose and pharmacokinetic parameters for rosuvastatin and metformin were compared between combination and monotherapy. Adverse events were investigated and evaluated based on subject interviews and physical examinations. FINDINGS: Among the 36 enrolled subjects, 31 completed the study. The coadministration of rosuvastatin with metformin produced a significant pharmacokinetic interaction in rosuvastatin Css,max, with the 90% CI for the geometric mean ratio (coadministration:monoadministration) being 110.27% to 136.39% (P = 0.0029), whereas no significant interaction was observed in rosuvastatin AUCtau, yielding the 90% CI of 104.41% to 118.95%. When metformin was coadministered with rosuvastatin, no significant pharmacokinetic interaction was observed for Css,max and AUCtau of metformin, yielding the 90% CIs of the geometric mean ratio for coadministration to monoadministration as 87.38% to 102.54% and 86.70% to 99.08%, respectively. Overall, 19 mild and 1 moderate adverse events occurred in 12 subjects, with no significant differences in the incidence among the 3 treatments. IMPLICATIONS: Although the Css,max of rosuvastatin was significantly influenced by coadministration with metformin, the degree of interaction seen was considered clinically insignificant, with no significant interaction observed in the other pharmacokinetic measures between the 2 drugs. These results imply that drug effects of rosuvastatin and metformin will also not be significantly influenced by coadministration of the 2 drugs. All treatments were well tolerated and no serious adverse events occurred. ClinicalTrials.gov identifier: NCT01526317.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers
Yonsei Authors
Roh, Hye Rang(노혜랑)
Park, Kyungsoo(박경수) ORCID logo https://orcid.org/0000-0002-6972-1143
Son, Han kil(손한길)
Lee, Dong Hwan(이동환)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.